Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) had its price objective decreased by stock analysts at Canaccord Genuity Group from $153.00 to $149.00 in a report issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Canaccord Genuity Group's price target indicates a potential upside of 308.22% from the stock's current price.
Other analysts also recently issued reports about the company. Wedbush reduced their price objective on Nektar Therapeutics from $80.00 to $50.00 and set a "neutral" rating for the company in a research note on Wednesday, September 23rd. TD Cowen raised Nektar Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Leerink Partners started coverage on Nektar Therapeutics in a research note on Monday, October 12th. They issued an "outperform" rating and a $130.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $185.00 target price on shares of Nektar Therapeutics in a report on Friday, October 2nd. Finally, BTIG Research reissued a "buy" rating and issued a $178.00 target price on shares of Nektar Therapeutics in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nektar Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $130.33.
Get Our Latest Analysis on Nektar Therapeutics
Nektar Therapeutics Trading Down 2.1%
Shares of Nektar Therapeutics stock traded down $0.77 during trading on Monday, reaching $36.50. The company's stock had a trading volume of 320,642 shares, compared to its average volume of 1,058,947. The company has a 50-day moving average price of $48.47 and a two-hundred day moving average price of $64.54. The firm has a market cap of $1.25 billion, a PE ratio of -5.66 and a beta of 1.44. Nektar Therapeutics has a fifty-two week low of $33.40 and a fifty-two week high of $109.00.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. The firm had revenue of $9.39 million during the quarter, compared to the consensus estimate of $10.27 million. On average, analysts predict that Nektar Therapeutics will post -8.08 earnings per share for the current fiscal year.
Insider Activity at Nektar Therapeutics
In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the sale, the chief executive officer directly owned 54,627 shares in the company, valued at approximately $3,932,051.46. The trade was a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company's stock.
Hedge Funds Weigh In On Nektar Therapeutics
Several hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC purchased a new position in shares of Nektar Therapeutics during the first quarter valued at approximately $19,786,000. Two Seas Capital LP boosted its stake in Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company's stock worth $202,582,000 after buying an additional 253,744 shares during the last quarter. Braidwell LP grew its holdings in Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company's stock valued at $33,063,000 after buying an additional 250,916 shares during the period. Bank of New York Mellon Corp purchased a new stake in Nektar Therapeutics in the 2nd quarter valued at about $6,706,000. Finally, ACT Capital Partners L.P. purchased a new stake in Nektar Therapeutics in the 3rd quarter valued at about $5,473,000. 75.88% of the stock is owned by hedge funds and other institutional investors.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.